<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">
 <list list-type="order">
  <list-item>
   <p id="Par14">There are no controlled studies on the use of ACE inhibitors and ARBs in patients with COVID-19.</p>
  </list-item>
  <list-item>
   <p id="Par15">The clinical evidence is inconclusive. While one study in China did not find any association of ACE inhibitor use with severity of disease, there was an increased mortality in patients with COVID-19 receiving ACE inhibitors and ARBs in another study [
    <xref ref-type="bibr" rid="CR29">29</xref>, 
    <xref ref-type="bibr" rid="CR30">30</xref>]. One study in the USA did not find any significant difference in mortality in patients who received ACE inhibitors and ARBs and those who did not [
    <xref ref-type="bibr" rid="CR31">31</xref>]. A recently published study in 1128 patients hospitalised with COVID-19 in nine hospitals in Hubei, China showed significantly reduced all-cause mortality with the use of ACE inhibitors or ARBs compared with other anti-hypertensive drugs [
    <xref ref-type="bibr" rid="CR32">32</xref>].
   </p>
  </list-item>
  <list-item>
   <p id="Par16">Many patients with COVID-19 have shown hypokalemia indicating activation of RAS [
    <xref ref-type="bibr" rid="CR33">33</xref>], and ACE inhibitors and ARBs may have a role [
    <xref ref-type="bibr" rid="CR34">34</xref>].
   </p>
  </list-item>
 </list>
</p>
